Adverum Biotechnologies, Inc. (ADVM)
Fuera de horario:
Adverum Biotechnologies, Inc.
100 Cardinal Way
Redwood City, CA 94063
United States
650 656 9323
https://adverum.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 121
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Laurent Fischer | President, CEO & Director | 1.02M | N/D | 1964 |
| Ms. Linda M. Rubinstein M.A. | CFO, Principal Financial Officer & Principal Accounting Officer | 940.99k | N/D | 1967 |
| Mr. Kishor Peter Soparkar J.D. | Chief Operating Officer | 674.98k | N/D | 1972 |
| Dr. Setareh Seyedkazemi Pharm.D. | Chief Development Officer | 656.84k | N/D | 1975 |
| Dr. R. Andrew Ramelmeier Ph.D. | Chief Technology Officer | N/D | N/D | 1962 |
| Dr. Romuald Corbau Ph.D. | Chief Scientific Officer | N/D | N/D | 1969 |
| Mr. John W. Rakow J.D. | Senior VP & General Counsel | 954.24k | N/D | 1957 |
| Ms. Dena House | Chief People Officer | N/D | N/D | N/D |
| Ms. Carla Fiankan | Senior Vice President of Regulatory Affairs | N/D | N/D | N/D |
| Mr. Michael Steel | Senior Vice President of Quality | N/D | N/D | N/D |
Descripción
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Adverum Biotechnologies, Inc. a partir del 1 de abril de 2024 es 7. Las puntuaciones principales son Auditoría: 6; Junta: 5; Derechos del accionista: 8; Compensación: 9.
